Health Affairs, 26, no. 1 (2007): 186-194 doi: 10.1377/hlthaff.26.1.186 © 2007 by Project HOPE	New Online   McAllen, TX & Beyond: An Expert Roundtable   Geography & Reform   Medicaid or Insurance Exchange?   Siren Song of New GME   Public Plan Option: Pro & Con

This Article Figures Only Full Text (HTML) Reprint (PDF) Supplemental Exhibit Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Choudhry, N. K. Articles by Shrank, W. H. Search for Related Content PubMed PubMed Citation Articles by Choudhry, N. K. Articles by Shrank, W. H. Related Collections Access To Care Health Promotion/Disease Prevention Pharmaceuticals Health Spending Consumer Issues Cardiovascular Disease

Health Tracking

MARKETWATCH

Should Patients Receive Secondary Prevention Medications For Free After A Myocardial Infarction? An Economic Analysis

Taken in combination, aspirin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and statins (combination pharmacotherapy) greatly reduce cardiac events. These therapies are underused, even among patients with drug insurance. Out-of-pocket spending is a key barrier to adherence. We estimated the impact of providing combination pharmacotherapy without cost sharing ("full coverage") to insured patients after a myocardial infarction (MI). Under base-case assumptions, compared to standard coverage, three years of full coverage will reduce mortality and reinfarction rates and will save $5,974 per patient. Our analysis suggests that covering combination therapy for such patients will save both lives and money.

                      What's this?

This article has been cited by other articles:

				Y. Zhang, J. M. Donohue, J. R. Lave, G. O'Donnell, and J. P. Newhouse The Effect of Medicare Part D on Drug and Medical Spending N. Engl. J. Med., July 2, 2009; 361(1): 52 - 61. [Abstract] [Full Text] [PDF]

				N. K. Choudhry, J. L. Lee, J. Agnew-Blais, C. Corcoran, and W. H. Shrank Drug Company-Sponsored Patient Assistance Programs: A Viable Safety Net? Health Aff., May 1, 2009; 28(3): 827 - 834. [Abstract] [Full Text] [PDF]

				N. K. Choudhry Copayment Levels and Medication Adherence: Less Is More Circulation, January 27, 2009; 119(3): 365 - 367. [Full Text] [PDF]

				A. S. Kesselheim and N. K. Choudhry The International Pharmaceutical Market as a Source of Low-Cost Prescription Drugs for U.S. Patients Ann Intern Med, April 15, 2008; 148(8): 614 - 619. [Abstract] [Full Text] [PDF]

				N. K. Choudhry, A. R. Patrick, E. M. Antman, J. Avorn, and W. H. Shrank Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post-Myocardial Infarction Medicare Beneficiaries Circulation, March 11, 2008; 117(10): 1261 - 1268. [Abstract] [Full Text] [PDF]

				D. H. Smith, J. M. Kramer, N. Perrin, R. Platt, D. W. Roblin, K. Lane, M. Goodman, W. W. Nelson, X. Yang, and S. B. Soumerai A Randomized Trial of Direct-to-Patient Communication to Enhance Adherence to {beta}-Blocker Therapy Following Myocardial Infarction Arch Intern Med, March 10, 2008; 168(5): 477 - 483. [Abstract] [Full Text] [PDF]

				S. Schneeweiss, A. R. Patrick, M. Maclure, C. R. Dormuth, and R. J. Glynn Adherence to Statin Therapy Under Drug Cost Sharing in Patients With and Without Acute Myocardial Infarction: A Population-Based Natural Experiment Circulation, April 24, 2007; 115(16): 2128 - 2135. [Abstract] [Full Text] [PDF]

				T. Brennan and L. Reisman Value-Based Insurance Design And The Next Generation Of Consumer-Driven Health Care Health Aff., March 1, 2007; 26(2): w204 - w207. [Abstract] [Full Text] [PDF]